Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revenio Group OyjREVXF 79 EV-to-EBITDA is 15.43 as of Aug. 19, 2026, which is 51% below its 10-year median of 31.60. GuruFocus rates REVXF with a GF Score™ of 79/100 and a GF Value™ of $36.37. The stock has 2 warning signs investors should review. Among 513 Medical Devices & Instruments companies, Revenio Group Oyj ranks worse than 53.8% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Revenio Group Oyj's enterprise value is $460.2 Mil.
Revenio Group Oyj's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $29.8 Mil. Therefore, Revenio Group Oyj's EV-to-EBITDA for today is 15.43.
The historical rank and industry rank for Revenio Group Oyj's EV-to-EBITDA or its related term are showing as below:
REVXF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.15 Med: 31.6 Max: 75.23
Current: 15.69
During the past 13 years, the highest EV-to-EBITDA of Revenio Group Oyj was 75.23. The lowest was 12.15. And the median was 31.60.
REVXF's EV-to-EBITDA is ranked worse than 53.8% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.77
vs REVXF: 15.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Revenio Group Oyj (OTCPK:REVXF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Revenio Group Oyj's PE Ratio (TTM) for today is calculated as:
Revenio Group Oyj's share price for today is $16.41.
Revenio Group Oyj's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.687.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Revenio Group Oyj's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Revenio Group Oyj's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's EV-to-EBITDA falls into.
Revenio Group Oyj's current Enterprise Value is $460.2 Mil.
Revenio Group Oyj's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $29.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revenio Group Oyj (REVXF) has a EV-to-EBITDA of 15.43 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Revenio Group Oyj. This is 51% below median its historical median of 31.60. Over the past decade, Revenio Group Oyj's EV-to-EBITDA has ranged from 12.15 to 75.23. According to the industry distribution chart, Revenio Group Oyj ranks #276 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 53.8%.
Is Revenio Group Oyj's EV-to-EBITDA too high?
Revenio Group Oyj's current EV-to-EBITDA of 15.43 is 51% below median its 10-year median of 31.60. Over the past 10 years, this metric has ranged from a low of 12.15 to a high of 75.23. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.77. Revenio Group Oyj's value of 15.43 is 4.5% above this industry median. Based on the distribution chart, Revenio Group Oyj ranks #276 out of 513 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Revenio Group Oyj has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #276 out of 513 companies for EV-to-EBITDA. This places Revenio Group Oyj in the lower half of its industry. The industry median EV-to-EBITDA is 14.77. Revenio Group Oyj's value of 15.43 is 4.5% above this benchmark. Historically, Revenio Group Oyj's own EV-to-EBITDA has ranged from 12.15 to 75.23 over the past decade. While the company's 10-year median is 31.60 vs. the industry median of 14.77, Revenio Group Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.77, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current EV-to-EBITDA of 15.43 is 4.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Revenio Group Oyj. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current EV-to-EBITDA is 15.43, which is 51% below median its own 10-year median of 31.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Revenio Group Oyj (REVXF) has a current EV-to-EBITDA of 15.43. The stock's GF Value™ is $36.37, compared to a current price of $16.41 — trading 54.9% below its estimated fair value. The current EV-to-EBITDA is 15.43, which is 51% below median its 10-year median of 31.60 and 4.5% above the Medical Devices & Instruments industry median of 14.77. Revenio Group Oyj's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current EV-to-EBITDA is 15.43 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 54.9% below its estimated GF Value™ of $36.37.
Key valuation signals for REVXF:
EV-to-EBITDA: 15.43 (51% below median its 10-year median of 31.60)
GF Value™: $36.37 vs. price of $16.41 (54.9% below fair value)
Industry Position: 4.5% above the Medical Devices & Instruments median (#276 of 513)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
79GF Score
Get the complete analysis for REVXF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
